- Home
- MOGO vs INKT Comparison
MOGO vs INKT Comparison
Compare MOGO & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOGO
- INKT
- Stock Information
- Founded
- MOGO 2003
- INKT 2017
- Country
- MOGO Canada
- INKT United States
- Employees
- MOGO N/A
- INKT N/A
- Industry
- MOGO
- INKT Medicinal Chemicals and Botanical Products
- Sector
- MOGO
- INKT Health Care
- Exchange
- MOGO Nasdaq
- INKT Nasdaq
- Market Cap
- MOGO 25.1M
- INKT 28.9M
- IPO Year
- MOGO N/A
- INKT 2021
- Fundamental
- Price
- MOGO $2.20
- INKT $7.04
- Analyst Decision
- MOGO Strong Buy
- INKT Strong Buy
- Analyst Count
- MOGO 1
- INKT 2
- Target Price
- MOGO $4.00
- INKT $37.50
- AVG Volume (30 Days)
- MOGO 14.0M
- INKT 14.8K
- Earning Date
- MOGO 08-07-2025
- INKT 08-12-2025
- Dividend Yield
- MOGO N/A
- INKT N/A
- EPS Growth
- MOGO N/A
- INKT N/A
- EPS
- MOGO N/A
- INKT N/A
- Revenue
- MOGO $28,873,274.00
- INKT N/A
- Revenue This Year
- MOGO $59.16
- INKT N/A
- Revenue Next Year
- MOGO $6.17
- INKT N/A
- P/E Ratio
- MOGO N/A
- INKT N/A
- Revenue Growth
- MOGO 0.62
- INKT N/A
- 52 Week Low
- MOGO $0.74
- INKT $4.56
- 52 Week High
- MOGO $3.83
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- MOGO 70.27
- INKT 40.47
- Support Level
- MOGO $1.17
- INKT $6.91
- Resistance Level
- MOGO $3.83
- INKT $7.51
- Average True Range (ATR)
- MOGO 0.22
- INKT 0.30
- MACD
- MOGO 0.11
- INKT -0.04
- Stochastic Oscillator
- MOGO 39.18
- INKT 0.00
About MOGO Mogo Inc.
Mogo Inc is a Canadian-based financial technology company. It offers a finance application to consumers with solutions that help them to control their financial health. At Mogo, users can sign up for a free account and get access to products and solutions that help users to monitor their credit score, protect themselves from identity fraud, control their spending, and borrow responsibly. Company offers digital loans and mortgages and also offer a digital payments platform that powers next-generation card programs for both established global corporations and innovative fintech companies in Europe and Canada.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.